Diligence memo · auto-generated · as of July 2, 2026
ProciseDX Inc.
ProciseDX Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
ProciseDX Inc. operates in Biotechnology, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ProciseDX Inc. has raised $9.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.0M on 2020-07-17.
Most recent recorded round closed around 2020-07-17.
Valuation (modeled)modeled
Provath models ProciseDX Inc. at approximately $317M (range $9.8M–$1.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.75× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 6.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 54% of Biotechnology peers (4291 compared).
Modeled value ranks above 77% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., Arrakis Therapeutics, Inc., TechAccel, LLC, Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.